As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Treatment Study for Patients with Node-Positive Breast Cancer
This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy X-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.
In order to participate you must meet the following criteria:
- Have clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to start of neoadjuvant chemotherapy).
- Have no inflammatory breast cancer.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
This is a partial list of elgibility requirements.